Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Clinical Therapeutics Valentin al Jalali, Peter Matzneller, Beatrix Wulkersdorfer, Scharon Chou, Soma Bahmany, Birgit C. P. Koch, Markus Zeitlinger DOI: 10.1128/AAC.01375-20 ABSTRACT Continuous infusion (CON) of fosfomycin has been proposed as potentially advantageous in certain clinical scenarios. However, no clinical data on the pharmacokinetics (PK) of fosfomycin after CON are available to date.
Background Telavancin is a novel lipoglycoprotein antibiotic with MRSA activity. To date, tissue pharmacokinetics (PK) and plasma protein binding of the drug are insufficiently described. Objectives To investigate tissue PK and plasma protein binding of telavancin in healthy volunteers. Methods Eight male healthy subjects received a single dose of 10 mg/kg of body weight of telavancin as an intravenous infusion over 1 h.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.